易瑞生物（300942）7月14日主力资金净流入8728.44万元

Group 1 - The core viewpoint of the news highlights the significant increase in the stock price of EasyRegen Biotech, which closed at 10.8 yuan, marking a 12.15% rise as of July 14, 2025 [1] - The company reported a total revenue of 49.34 million yuan for Q1 2025, reflecting a year-on-year growth of 35.28%, and a net profit attributable to shareholders of 3.35 million yuan, up 52.95% year-on-year [1] - The company has a strong liquidity position with a current ratio of 5.467 and a quick ratio of 5.161, alongside a debt-to-asset ratio of 39.97% [1] Group 2 - EasyRegen Biotech has made investments in 23 companies and participated in 750 bidding projects, indicating active engagement in business expansion [2] - The company holds 27 trademark registrations and 148 patents, showcasing its commitment to innovation and intellectual property [2] - Additionally, the company possesses 87 administrative licenses, further emphasizing its operational capabilities [2]